180 related articles for article (PubMed ID: 25333264)
1. Overexpression of platelet-derived growth factor receptor alpha promotes tumor progression and indicates poor prognosis in hepatocellular carcinoma.
Wei T; Zhang LN; Lv Y; Ma XY; Zhi L; Liu C; Ma F; Zhang XF
Oncotarget; 2014 Nov; 5(21):10307-17. PubMed ID: 25333264
[TBL] [Abstract][Full Text] [Related]
2. The PDGFRα-laminin B1-keratin 19 cascade drives tumor progression at the invasive front of human hepatocellular carcinoma.
Govaere O; Petz M; Wouters J; Vandewynckel YP; Scott EJ; Topal B; Nevens F; Verslype C; Anstee QM; Van Vlierberghe H; Mikulits W; Roskams T
Oncogene; 2017 Nov; 36(47):6605-6616. PubMed ID: 28783171
[TBL] [Abstract][Full Text] [Related]
3. Platelet-derived growth factor receptor α in hepatocellular carcinoma is a prognostic marker independent of underlying liver cirrhosis.
Yu JH; Kim JM; Kim JK; Choi SJ; Lee KS; Lee JW; Chang HY; Lee JI
Oncotarget; 2017 Jun; 8(24):39534-39546. PubMed ID: 28465473
[TBL] [Abstract][Full Text] [Related]
4. Platelet-derived growth factor receptor-alpha: a novel therapeutic target in human hepatocellular cancer.
Stock P; Monga D; Tan X; Micsenyi A; Loizos N; Monga SP
Mol Cancer Ther; 2007 Jul; 6(7):1932-41. PubMed ID: 17604334
[TBL] [Abstract][Full Text] [Related]
5. Overexpressed HDGF as an independent prognostic factor is involved in poor prognosis in Chinese patients with liver cancer.
Zhou Y; Zhou N; Fang W; Huo J
Diagn Pathol; 2010 Sep; 5():58. PubMed ID: 20846397
[TBL] [Abstract][Full Text] [Related]
6. Ribosomal protein S15a promotes tumor angiogenesis via enhancing Wnt/β-catenin-induced FGF18 expression in hepatocellular carcinoma.
Guo P; Wang Y; Dai C; Tao C; Wu F; Xie X; Yu H; Zhu Q; Li J; Ye L; Yu F; Shan Y; Yu Z; Dhanasekaran R; Zheng R; Chen G
Oncogene; 2018 Mar; 37(9):1220-1236. PubMed ID: 29242604
[TBL] [Abstract][Full Text] [Related]
7. Increased expression of SLC46A3 to oppose the progression of hepatocellular carcinoma and its effect on sorafenib therapy.
Zhao Q; Zheng B; Meng S; Xu Y; Guo J; Chen LJ; Xiao J; Zhang W; Tan ZR; Tang J; Chen L; Chen Y
Biomed Pharmacother; 2019 Jun; 114():108864. PubMed ID: 30981107
[TBL] [Abstract][Full Text] [Related]
8. TRIB3 promotes hepatocellular carcinoma growth and predicts poor prognosis.
Wang XJ; Li FF; Zhang YJ; Jiang M; Ren WH
Cancer Biomark; 2020; 29(3):307-315. PubMed ID: 32716348
[TBL] [Abstract][Full Text] [Related]
9. Long noncoding RNA CPS1-IT1 suppresses the metastasis of hepatocellular carcinoma by regulating HIF-1α activity and inhibiting epithelial-mesenchymal transition.
Wang TH; Yu CC; Lin YS; Chen TC; Yeh CT; Liang KH; Shieh TM; Chen CY; Hsueh C
Oncotarget; 2016 Jul; 7(28):43588-43603. PubMed ID: 27248828
[TBL] [Abstract][Full Text] [Related]
10. Up-regulation of platelet-derived growth factor-A is responsible for the failure of re-initiated interferon alpha treatment in hepatocellular carcinoma.
Zhang JB; Sun HC; Jia WD; Zhuang PY; Qian YB; Zhu XD; Kong LQ; Wang L; Wu WZ; Tang ZY
BMC Cancer; 2012 Oct; 12():439. PubMed ID: 23025904
[TBL] [Abstract][Full Text] [Related]
11. HOXB7 accelerates the malignant progression of hepatocellular carcinoma by promoting stemness and epithelial-mesenchymal transition.
Huan HB; Yang DP; Wen XD; Chen XJ; Zhang L; Wu LL; Bie P; Xia F
J Exp Clin Cancer Res; 2017 Jun; 36(1):86. PubMed ID: 28646927
[TBL] [Abstract][Full Text] [Related]
12. Long noncoding RNA AWPPH promotes hepatocellular carcinoma progression through YBX1 and serves as a prognostic biomarker.
Zhao X; Liu Y; Yu S
Biochim Biophys Acta Mol Basis Dis; 2017 Jul; 1863(7):1805-1816. PubMed ID: 28428004
[TBL] [Abstract][Full Text] [Related]
13. CISD2 associated with proliferation indicates negative prognosis in patients with hepatocellular carcinoma.
Chen B; Shen S; Wu J; Hua Y; Kuang M; Li S; Peng B
Int J Clin Exp Pathol; 2015; 8(10):13725-38. PubMed ID: 26722601
[TBL] [Abstract][Full Text] [Related]
14. Long non-coding RNA CARLo-5 expression is associated with disease progression and predicts outcome in hepatocellular carcinoma patients.
Wang F; Xie C; Zhao W; Deng Z; Yang H; Fang Q
Clin Exp Med; 2017 Feb; 17(1):33-43. PubMed ID: 26433964
[TBL] [Abstract][Full Text] [Related]
15. Endoplasmic reticulum resident oxidase ERO1-Lalpha promotes hepatocellular carcinoma metastasis and angiogenesis through the S1PR1/STAT3/VEGF-A pathway.
Yang S; Yang C; Yu F; Ding W; Hu Y; Cheng F; Zhang F; Guan B; Wang X; Lu L; Rao J
Cell Death Dis; 2018 Oct; 9(11):1105. PubMed ID: 30377291
[TBL] [Abstract][Full Text] [Related]
16. Expression and prognostic significance of epithelial tissue-specific transcription factor ESE3 in hepatocellular carcinoma.
Lyu Z; Ma M; Xu Y; Wang X; Zhu Y; Ren W; Li T
Int J Clin Oncol; 2020 Jul; 25(7):1334-1345. PubMed ID: 32347431
[TBL] [Abstract][Full Text] [Related]
17. A novel lncRNA, TCONS_00006195, represses hepatocellular carcinoma progression by inhibiting enzymatic activity of ENO1.
Yu S; Li N; Huang Z; Chen R; Yi P; Kang R; Tang D; Hu X; Fan X
Cell Death Dis; 2018 Dec; 9(12):1184. PubMed ID: 30518748
[TBL] [Abstract][Full Text] [Related]
18. The mu-opioid receptor is a molecular marker for poor prognosis in hepatocellular carcinoma and represents a potential therapeutic target.
Chen DT; Pan JH; Chen YH; Xing W; Yan Y; Yuan YF; Zeng WA
Br J Anaesth; 2019 Jun; 122(6):e157-e167. PubMed ID: 30915986
[TBL] [Abstract][Full Text] [Related]
19. Downregulation of miRNA-638 promotes angiogenesis and growth of hepatocellular carcinoma by targeting VEGF.
Cheng J; Chen Y; Zhao P; Liu X; Dong J; Li J; Huang C; Wu R; Lv Y
Oncotarget; 2016 May; 7(21):30702-11. PubMed ID: 27120793
[TBL] [Abstract][Full Text] [Related]
20. CD151 modulates expression of matrix metalloproteinase 9 and promotes neoangiogenesis and progression of hepatocellular carcinoma.
Shi GM; Ke AW; Zhou J; Wang XY; Xu Y; Ding ZB; Devbhandari RP; Huang XY; Qiu SJ; Shi YH; Dai Z; Yang XR; Yang GH; Fan J
Hepatology; 2010 Jul; 52(1):183-96. PubMed ID: 20578262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
